Clinical Trial Update: Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas [Phase 1]

View source ↗

Summary

This update describes a Phase 1 clinical trial evaluating locoregional administration of EGFR/IL13Rα2 Pool-CAR T cells for recurrent or progressive high-grade g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma

Drugs mentioned

• EGFR/IL13Rα2 Pool-CAR T Cells

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype | Phase 1 | Status: NOT_YET_RECRUITING